Drug Trial Radar · NCT06014190
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
460
Planned (sponsor's estimate)
Start
Dec 18, 2023
Primary completion
Dec 31, 2025
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20089 as monotherapy in patients with recurrent or metastatic ovarian cancer and endometrial cancer.
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Endometrial Cancer
Interventions
HS-20089Drug
All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: From the first dose up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Cancer Hospital
Hefei, Anfei, China · Recruiting
Lingying Wu
Beijing, Beijing Municipality, China · Recruiting
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing University cancer Hospital
Chongqing, Chongqing Municipality, China · Suspended
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat-Sen Memorial Hospital Sun Yat-Sen University
Guangzhou, Guangdong, China · Recruiting
Guangxi Cancer Hospital
Nanning, Guangxi, China · Recruiting
Hainan General Hospital
Haikou, Hainan, China · Recruiting
The fourth Hospital of Heibei Medical University
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Hubei Cancer University
Wuhan, Hubei, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hosipital
Changsha, Hunan, China · Recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Recruiting
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China · Suspended
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Recruiting
The first Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China · Recruiting
Tianjin Medical University cancer institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Affiliated Cancer Hospital of Xinjiang Medical University
Xinjiang, Xinjiang, China · Recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Recruiting
Zhejiang Cancer Hospital
Hanzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.